Josh Nathan-Kazis, Barron's

Josh Nathan-Kazis

Barron's

Mountain View, CA, United States

Contact Josh

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • Unknown
Past:
  • Barron's
  • Moneyish

Past articles by Josh:

Price Negotiations Are About to Reshape the Drug Industry

A new U.S. law could push big pharma companies toward more diverse drug pipelines and away from an era of high-priced and complex medicines. → Read More

Covid Isn't Going Away. New Drugs Are Coming.

Drug makers are preparing everything from a vaccine that comes as a pill to a better version of Paxlovid. → Read More

3 Big Vaccine Developments Investors Should Watch in 2023

This year will bring news on mRNA flu vaccines and the jabs for RSV and Covid-19 from companies like Pfizer, Moderna, and GSK. → Read More

CVS Wants to Be America’s Healthcare Provider. All It Needs Now Are Doctors.

CVS Health staked its future on primary care, but a year later it still hasn't made an acquisition. Should investors be worried? → Read More

CVS Wants to Be America’s Healthcare Provider. All It Needs Now Are Doctors.

CVS Health staked its future on primary care, but a year later it still hasn't made an acquisition. Should investors be worried? → Read More

Can We Beat Alzheimer’s? Biogen and Eisai’s Latest Drug Trial Will Offer Clues.

The company’s last attempt to target the devastating disease flopped. Results from a key trial of Biogen and Eisai’s new drug, lecanemab, are coming soon—and have huge implications. → Read More

The FDA Is Giving Amylyx Another Chance on Its ALS Drug. What to Expect.

The decision to give the treatment a second hearing may be a positive sign for the drug's eventual approval. → Read More

FDA Advisers Back Moderna and Pfizer Covid Vaccines for Young Children

Children under 5 years old are on their way to being able to be vaccinated. → Read More

Who Will Lead Biogen? This Analyst Offers Some Likely Picks.

The executive who replaces Michel Vounatsos will inherit a large-cap biotech facing significant challenges. → Read More

Living With the Pandemic: Antivirals Will Make a Big Difference

The virus can change quickly, and another Omicron-like wave is possible. How to think about the evolution of Covid over the next two years. → Read More

The FDA Has a New Chief. Here Are 5 Key Decisions on Drugs to Watch.

As Dr. Robert Califf takes the reins, investors will be watching for what the agency does on ALS and Alzheimer’s drugs, Covid vaccines, and others. → Read More

Why AstraZeneca Could Be a Sound Long-Term Bet

It's the big pharma company that "has the best stuff with the least warts,” says T. Rowe Price’s Ziad Bakri. → Read More

8 Biotech Stocks So Cheap That Their Technology Is Effectively Free

The beleaguered sector is showing no real signs of recovery. That could spell an opportunity for some stocks. → Read More

Pfizer Stock Drops After Earnings. Guidance Fell Short of Estimates.

The firm expects record revenue in 2022 and sees a big increase in sales of its Covid antiviral. Total revenue projections fell short of expectations. → Read More

Time to Lift All Covid Restrictions? As Omicron Eases, Some Public Health Experts Call for a Pullback Soon.

A pullback, even if largely symbolic, could give a boost to economic activity. → Read More

How Omicron Is Changing Vaccine and Therapeutic Strategies

Drug companies and regulators are making adjustments to cope with the challenges posed by the Covid-19 variant. → Read More

Many Hospitals Are Getting Overwhelmed. It’s a Crisis That Could Affect Healthcare for Years to Come.

Omicron wave shows how two years of pandemic has weakened the healthcare workforce in the U.S. → Read More

Booster Rollout Could Expand as Covid Cases Rise

A broader push could shore up the stocks of the vaccine makers. → Read More

Pfizer Shows Its R&D Is Strong. That Makes Its Stock a Good Long-Term Bet.

Successes with its Covid-19 vaccine and antiviral pill appear to validate a strategic shift by the drugmaker. → Read More

Pfizer Shows Its R&D Is Strong. That Makes Its Stock a Good Long-Term Bet.

Successes with its Covid-19 vaccine and antiviral pill appear to validate a strategic shift by the drugmaker. → Read More